. . . . . . . "[In conclusion, HDACi in combination with erlotinib might serve as a treatment option for newly diagnosed, treatment-na�ve tumors irrespective of their EGFR status, as well as for treatment-refractory, EGFR-overexpressing GBM.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:12:11+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .